about
2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemiaProstaglandin E2 synthesis and secretion: the role of PGE2 synthasesThe New York City Rheumatology Objective Structured Clinical Examination: five-year data demonstrates its validity, usefulness as a unique rating tool, objectivity, and sensitivity to change.Drug-induced myopathies.Hyperuricemia and gout: new insights into pathogenesis and treatment.Designing and implementing INTREPID, an intensive program in translational research methodologies for new investigatorsAdenosine A(2A) receptors play a role in the pathogenesis of hepatic cirrhosisEffect of cyclooxygenase inhibition on cholesterol efflux proteins and atheromatous foam cell transformation in THP-1 human macrophages: a possible mechanism for increased cardiovascular risk.Periodontal disease and the oral microbiota in new-onset rheumatoid arthritisSex differences in gout characteristics: tailoring care for women and men.Statins as antiinflammatory and immunomodulatory agents: a future in rheumatologic therapy?Colchicine: old and newPresence of gout is associated with increased prevalence and severity of knee osteoarthritis among older men: results of a pilot studyTeaching Translational Research to Medical Students: The New York University School of Medicine's Master's of Science in Clinical Investigation Dual-Degree Program.Effect of Colchicine on Platelet-Platelet and Platelet-Leukocyte Interactions: a Pilot Study in Healthy SubjectsThe role of the synovial fibroblast in rheumatoid arthritis: cartilage destruction and the regulation of matrix metalloproteinases.Modes of action of aspirin-like drugs: salicylates inhibit erk activation and integrin-dependent neutrophil adhesion.2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis.Interleukin-6 in the pathogenesis of rheumatoid arthritis.The role of Ras signaling in lupus T lymphocytes: biology and pathogenesis.Update on gout: pathophysiology and potential treatments.Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout.RS3PE presenting in a unilateral pattern: case report and review of the literature.Update on fibromyalgia therapy.Update on the management of hyperuricemia and gout.Integrin-dependent homotypic adhesion of neutrophils. Arachidonic acid activates Raf-1/Mek/Erk via a 5-lipoxygenase- dependent pathway.The anti-inflammatory effects of prostaglandins.Febuxostat: a new agent for lowering serum urate.SOMOSAT: Utility of a web-based self-assessment tool in undergraduate medical education.Hyperuricemia, gout, and cardiovascular disease--an important "muddle".New treatments for gout.The role of uric acid and other crystals in osteoarthritis.Gout and its comorbidities.Drugs causing muscle disease.The year in gout - 2010-2011.New therapies for gout.The year in gout: 2012-2013 - a walk through the 2012 ACR Gout Treatment Guidelines.Hyperuricemia, gout, and related comorbidities: cause and effect on a two-way street.Co-occurrence of Kikuchi-Fujimoto's disease and Still's disease: case report and review of previously reported cases.The causes of drug-induced muscle toxicity.
P50
Q24612292-1C557009-5164-43B7-97AE-2C4471D199FFQ28302274-F009339D-4C8D-4BB7-B138-12377AA66355Q33516941-FAA4E940-8664-44CD-989E-D20DE3F69414Q33517785-AFE3A609-5C2D-4C8E-9966-DAA0504DC301Q34699501-47C320B8-64E9-4646-965A-26C2D00633C4Q34714292-A84CA8F0-F9EE-446D-B4DE-0FDA75AF4054Q35546429-FBC5E1C2-10B3-46AB-AFD2-794E6B748BCCQ35769055-F3F8CD78-BC25-4924-955F-34E50BC9089DQ36191888-185598E8-37D9-4B57-82A3-0DC96AE7FB87Q36307823-9CAF71A0-F1BE-4B8E-A2BB-03C281975EEAQ36382202-4CD8297F-9548-49C1-8894-A8EE2A1C9E8EQ36384995-0579DF5C-C81B-47FF-BA65-EA1F73ED4AA7Q36468332-CE38C329-EC32-45CC-A91A-D5FD1BA202F9Q36510424-AE5A6E60-E936-42C3-A628-6C32BD89EB1CQ36578681-B1CB262F-B053-4203-8770-A7929A23444DQ36661140-F347BB6D-0BC1-43A7-B42F-F4E882343FD1Q36738131-B6D592D1-1129-4422-B7AB-32BEF9D038D5Q36870924-A6539F75-7D67-4859-9D6B-3B9717FC9CF4Q36914424-BB999A44-0A6B-43C5-8A63-83B99DEF8678Q36959410-262C9029-A514-45D6-A6A9-2C538AC4E8C7Q37049706-AE1780A6-9C8C-4B45-90BB-D04E7BD9BE1AQ37070180-B5C26EB6-BF0F-4ABA-AC21-21D6718FD67CQ37179774-CE55CA25-F05E-42A7-A30D-3BCF36D75C35Q37203027-40F5F613-1548-432B-A86C-4662B9726780Q37304237-6EE373B5-2E23-4392-A566-5123D03EA1AFQ37387155-CB08503F-D2BB-4FC2-82E1-C2961500B747Q37400560-EE525602-92BE-4427-800B-EC890FCBA547Q37508678-48786817-539F-400D-BF2C-B42EFA9430D6Q37610329-73C97919-C698-4761-A04A-96F743240D65Q37620416-9EA6DF53-7618-412A-AFA6-F10102F4CF01Q37737165-9040A8D2-BCF6-4D89-A7F3-92C2FABDF9C5Q37738122-64628E16-9E8C-4176-97D1-4496D6216AEEQ37802407-2657B8B0-AD81-455F-A74F-C82E6931AC73Q37858693-DA12927E-9B11-4DE0-B01D-537B3CC57049Q37950505-DF93EC20-905C-4973-91BB-39EF776D98B6Q38074709-6182823B-5C2A-4611-8EDF-12F1BF70C8C1Q38154942-324DB43E-9A50-4E9A-B104-D96901EEDE95Q38220913-5C1C8FED-F034-462F-A4CC-DD6B0399C148Q38237448-E70927A0-4F44-4A6F-BF41-95BFB2D3A5ACQ38246314-8D40B9B4-4C63-40EF-A1ED-D21E61FCCA99
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Michael Pillinger
@ast
Michael Pillinger
@en
Michael Pillinger
@es
Michael Pillinger
@nl
Michael Pillinger
@sl
type
label
Michael Pillinger
@ast
Michael Pillinger
@en
Michael Pillinger
@es
Michael Pillinger
@nl
Michael Pillinger
@sl
prefLabel
Michael Pillinger
@ast
Michael Pillinger
@en
Michael Pillinger
@es
Michael Pillinger
@nl
Michael Pillinger
@sl
P106
P2038
Michael_Pillinger
P31
P496
0000-0003-3168-1542